DK2542225T3 - Rifaximinpulver, fremgangsmåde til deres fremstilling og styret frigivelsessammensætninger indeholdende rifaximinen anvendelig til tilvejebringelse af en langtidsvirkning - Google Patents
Rifaximinpulver, fremgangsmåde til deres fremstilling og styret frigivelsessammensætninger indeholdende rifaximinen anvendelig til tilvejebringelse af en langtidsvirkningInfo
- Publication number
- DK2542225T3 DK2542225T3 DK11714663.9T DK11714663T DK2542225T3 DK 2542225 T3 DK2542225 T3 DK 2542225T3 DK 11714663 T DK11714663 T DK 11714663T DK 2542225 T3 DK2542225 T3 DK 2542225T3
- Authority
- DK
- Denmark
- Prior art keywords
- rifaximine
- powder
- preparation
- providing
- long
- Prior art date
Links
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title 2
- 229960003040 rifaximin Drugs 0.000 title 2
- 238000013270 controlled release Methods 0.000 title 1
- 230000005923 long-lasting effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000843 powder Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2010A000370A IT1398550B1 (it) | 2010-03-05 | 2010-03-05 | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| PCT/IB2011/050933 WO2011107970A2 (en) | 2010-03-05 | 2011-03-04 | Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2542225T3 true DK2542225T3 (da) | 2014-11-17 |
Family
ID=42697389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11714663.9T DK2542225T3 (da) | 2010-03-05 | 2011-03-04 | Rifaximinpulver, fremgangsmåde til deres fremstilling og styret frigivelsessammensætninger indeholdende rifaximinen anvendelig til tilvejebringelse af en langtidsvirkning |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8748447B2 (enExample) |
| EP (1) | EP2542225B1 (enExample) |
| JP (1) | JP5932669B2 (enExample) |
| KR (1) | KR101663491B1 (enExample) |
| CN (1) | CN102781432B (enExample) |
| AU (1) | AU2011222432B2 (enExample) |
| BR (1) | BR112012021681A8 (enExample) |
| CA (1) | CA2787123C (enExample) |
| CL (1) | CL2012002124A1 (enExample) |
| CO (1) | CO6551760A2 (enExample) |
| DK (1) | DK2542225T3 (enExample) |
| EA (1) | EA022324B1 (enExample) |
| ES (1) | ES2496771T3 (enExample) |
| HR (1) | HRP20140876T1 (enExample) |
| IL (1) | IL220792A (enExample) |
| IT (1) | IT1398550B1 (enExample) |
| MX (1) | MX2012010233A (enExample) |
| NZ (1) | NZ602230A (enExample) |
| PL (1) | PL2542225T3 (enExample) |
| PT (1) | PT2542225E (enExample) |
| RS (1) | RS53609B1 (enExample) |
| SG (1) | SG182523A1 (enExample) |
| SI (1) | SI2542225T1 (enExample) |
| TN (1) | TN2012000362A1 (enExample) |
| UA (1) | UA107208C2 (enExample) |
| WO (1) | WO2011107970A2 (enExample) |
| ZA (1) | ZA201205537B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1698630T3 (pl) | 2005-03-03 | 2014-12-31 | Alfasigma Spa | Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| US8952159B2 (en) | 2009-12-28 | 2015-02-10 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
| IT1398550B1 (it) * | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| WO2011110930A2 (en) * | 2010-03-10 | 2011-09-15 | Lupin Limited | Rifaximin ready-to-use suspension |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| WO2014091432A1 (en) * | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
| WO2016019372A1 (en) * | 2014-08-01 | 2016-02-04 | Bioxcel Corporation | Methods for reformulating and repositioning pharmaceutical data and devices thereof |
| WO2016063289A2 (en) * | 2014-10-22 | 2016-04-28 | Strides Arcolab Limited | Pharmaceutical tablet compositions comprising rifaximin |
| WO2016181276A1 (en) * | 2015-05-08 | 2016-11-17 | Wockhardt Limited | Stable pharmaceutical compositions comprising antibacterial agent |
| WO2017162725A1 (en) | 2016-03-24 | 2017-09-28 | Sandoz Ag | Pharmaceutical composition containing rifaximin alpha & delta |
| WO2017162726A1 (en) | 2016-03-24 | 2017-09-28 | Sandoz Ag | Storage stable composition comprising rifaximin alpha |
| PT3518924T (pt) | 2016-09-30 | 2022-10-27 | Salix Pharmaceuticals Inc | Formas de dispersão sólidas de rifaximina |
| WO2020208140A1 (en) * | 2019-04-12 | 2020-10-15 | Sandoz Ag | Rifaximin-containing granules |
| WO2023067485A1 (en) * | 2021-10-19 | 2023-04-27 | Zydus Lifesciences Limited | Pharmaceutical combinations |
| WO2025170483A1 (ru) * | 2024-02-07 | 2025-08-14 | Общество с ограниченной ответственностью "БИННОФАРМ ГРУПП" | Фармацевтическая композиция, обладающая антибиотической активностью |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
| DE3113139A1 (de) | 1981-04-01 | 1982-10-21 | Smit Transformatoren B.V., 6500 Nijmegen | "trockentransformator oder drosselspule mit luftkuehlung" |
| IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
| US5356625A (en) | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
| GB8816620D0 (en) | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
| WO1992000302A1 (en) | 1990-06-29 | 1992-01-09 | Gruppo Lepetit S.P.A. | Pure crystalline form of rifapentine |
| IT1253711B (it) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
| IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| JP4195728B2 (ja) | 1996-10-16 | 2008-12-10 | ナポ ファーマシューティカルズ，インコーポレーテッド | プロアントシアニジンポリマー止瀉組成物の腸溶製剤 |
| IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
| US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| US20030157174A1 (en) | 2000-03-23 | 2003-08-21 | Takayuki Tsukuda | Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| CN100338028C (zh) | 2000-10-31 | 2007-09-19 | 山道士有限公司 | 盐酸文拉法辛的晶形 |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
| US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
| US20080262024A1 (en) | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
| US7923553B2 (en) | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
| US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| PL1698630T3 (pl) | 2005-03-03 | 2014-12-31 | Alfasigma Spa | Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych |
| ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
| JP2010504314A (ja) * | 2006-09-22 | 2010-02-12 | シプラ・リミテッド | リファキシミン |
| ITMI20071241A1 (it) * | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
| ES2389358T5 (es) | 2007-07-06 | 2016-01-19 | Lupin Ltd. | Composiciones farmacéuticas de rifaximina |
| US8383151B2 (en) | 2007-07-06 | 2013-02-26 | Lupin Limited | Pharmaceutical compositions of rifaximin |
| WO2009008006A2 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
| US7709634B2 (en) * | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
| MX2010009389A (es) | 2008-02-25 | 2010-11-22 | Salix Pharmaceuticals Ltd | Formas de rifaximina y sus usos. |
| US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| WO2010044093A1 (en) | 2008-10-16 | 2010-04-22 | Strides Arcolab Limited | Formulations containing rifaximin |
| WO2010067072A1 (en) | 2008-12-10 | 2010-06-17 | Cipla Limited | Rifaximin complexes |
| IT1397617B1 (it) | 2009-04-20 | 2013-01-18 | Alfa Wassermann Spa | Nuovi derivati della rifamicina |
| AU2010312309B2 (en) | 2009-10-26 | 2016-10-06 | Thomas Julius Borody | Novel enteric combination therapy |
| SG10201501054TA (en) | 2009-10-27 | 2015-04-29 | Lupin Ltd | Solid dispersion of rifaximin |
| WO2011061748A1 (en) | 2009-11-19 | 2011-05-26 | Strides Arcolab Limited | Rifaximin premix |
| US20130202654A1 (en) | 2009-11-23 | 2013-08-08 | Cipla Limited | Topical Foam Composition |
| CN102724960A (zh) | 2009-11-23 | 2012-10-10 | 希普拉有限公司 | 局部泡沫组合物 |
| US8952159B2 (en) | 2009-12-28 | 2015-02-10 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
| CN101773465B (zh) | 2010-01-19 | 2012-11-07 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的聚合物胶束载药系统 |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| WO2011110930A2 (en) | 2010-03-10 | 2011-09-15 | Lupin Limited | Rifaximin ready-to-use suspension |
| JP2013527246A (ja) | 2010-06-03 | 2013-06-27 | サリックス ファーマシューティカルズ リミテッド | リファキシミンの型およびその使用 |
| EP2582707A4 (en) | 2010-06-16 | 2014-01-08 | Apotex Pharmachem Inc | POLYMORPHIC FORMS OF RIFAXIMINE |
| CA2804635C (en) | 2010-07-12 | 2019-09-10 | Salix Pharmaceuticals, Ltd. | Formulations of rifaximin and uses thereof |
| WO2012035544A2 (en) | 2010-09-13 | 2012-03-22 | Sequent Scientific Ltd. | A novel polymorphic form of rifaximin and process for its preparation |
| BR112013005772A2 (pt) | 2010-09-13 | 2019-09-24 | Cipla Ltd | composição compreendendo rifaximina na forma de pertículas, composição farmacêutica, uso de uma composição, método para tratar uma infecção bacteriana e processo para preparar uma composição farmacêutica |
| IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
| WO2012076832A1 (en) | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
| MX350448B (es) | 2011-02-11 | 2017-09-07 | Salix Pharmaceuticals Ltd | Formas de rifaximina y usos de las mismas. |
| WO2012150561A1 (en) | 2011-05-02 | 2012-11-08 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
| ITMI20110890A1 (it) | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| CA2876737A1 (en) | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
| WO2014091432A1 (en) | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
| ITMI20131307A1 (it) | 2013-08-02 | 2015-02-02 | A M S A Anonima Materie Sint & Affini S P A | Processo per la preparazione di refaximina k |
-
2010
- 2010-03-05 IT ITMI2010A000370A patent/IT1398550B1/it active
-
2011
- 2011-03-04 EP EP11714663.9A patent/EP2542225B1/en active Active
- 2011-03-04 KR KR1020127022961A patent/KR101663491B1/ko not_active Expired - Fee Related
- 2011-03-04 ES ES11714663.9T patent/ES2496771T3/es active Active
- 2011-03-04 SG SG2012051975A patent/SG182523A1/en unknown
- 2011-03-04 EA EA201290734A patent/EA022324B1/ru unknown
- 2011-03-04 HR HRP20140876AT patent/HRP20140876T1/hr unknown
- 2011-03-04 PL PL11714663T patent/PL2542225T3/pl unknown
- 2011-03-04 WO PCT/IB2011/050933 patent/WO2011107970A2/en not_active Ceased
- 2011-03-04 PT PT117146639T patent/PT2542225E/pt unknown
- 2011-03-04 JP JP2012555537A patent/JP5932669B2/ja not_active Expired - Fee Related
- 2011-03-04 CN CN201180012550.XA patent/CN102781432B/zh not_active Expired - Fee Related
- 2011-03-04 AU AU2011222432A patent/AU2011222432B2/en not_active Ceased
- 2011-03-04 MX MX2012010233A patent/MX2012010233A/es unknown
- 2011-03-04 NZ NZ602230A patent/NZ602230A/xx not_active IP Right Cessation
- 2011-03-04 SI SI201130298T patent/SI2542225T1/sl unknown
- 2011-03-04 US US13/582,676 patent/US8748447B2/en active Active
- 2011-03-04 BR BR112012021681A patent/BR112012021681A8/pt not_active Application Discontinuation
- 2011-03-04 DK DK11714663.9T patent/DK2542225T3/da active
- 2011-03-04 RS RS20140619A patent/RS53609B1/sr unknown
- 2011-03-04 CA CA2787123A patent/CA2787123C/en active Active
- 2011-04-03 UA UAA201208484A patent/UA107208C2/uk unknown
-
2012
- 2012-07-05 IL IL220792A patent/IL220792A/en active IP Right Grant
- 2012-07-17 TN TNP2012000362A patent/TN2012000362A1/en unknown
- 2012-07-23 ZA ZA2012/05537A patent/ZA201205537B/en unknown
- 2012-07-30 CO CO12127400A patent/CO6551760A2/es not_active Application Discontinuation
- 2012-07-31 CL CL2012002124A patent/CL2012002124A1/es unknown
-
2014
- 2014-04-24 US US14/261,337 patent/US9498442B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2542225T3 (da) | Rifaximinpulver, fremgangsmåde til deres fremstilling og styret frigivelsessammensætninger indeholdende rifaximinen anvendelig til tilvejebringelse af en langtidsvirkning | |
| ZA201404733B (en) | Novel benzopyran compounds, compositions and uses thereof | |
| DK2593463T3 (da) | Formuleringer af rifaximin og anvendelser deraf | |
| IL219912A (en) | History of isoxazoline, their use as insecticides and their instrumentation | |
| ZA201304297B (en) | Photochromic compounds and compositions | |
| PH12013501357A1 (en) | Photochromic compounds and compositions | |
| DK2691079T3 (da) | Bionedbrydelige sammensætninger, der er egnet til kontrolleret udløsning | |
| ZA201202474B (en) | Controlled release compositions | |
| HUE037747T2 (hu) | Nanostrukturált aprepirant készítmények, eljárások azok elõállítására és az azokat tartalmazó gyógyászati készítmények | |
| ZA201304210B (en) | Photochromic compounds and compositions | |
| SG11201401138RA (en) | Ion exchange compositions, methods for making and materials prepared therefrom | |
| DK2598500T3 (da) | Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen | |
| DK2533761T3 (da) | Fremgangsmåder og sammensætninger til fremstilling af aerosoler | |
| DK3766522T3 (da) | Automatiseret fremgangsmåde til fremstillingen af 18f-fluciclovin-sammensætninger | |
| ZA201401782B (en) | Chromobacterium formulations,compositions,metabolites and their uses | |
| EP2398469A4 (en) | ANTICHOLINERGIC CONTAINING DELAYED RELEASE COMPOSITION | |
| ZA201304212B (en) | Photochromic compounds and compositions | |
| HUE051509T2 (hu) | BSAS por | |
| EP2554168A4 (en) | PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE | |
| ZA201304016B (en) | Photochromic compounds, compositions and articles | |
| ZA201209576B (en) | Pest-resistant plants | |
| SI2665477T1 (sl) | Modificirano sproščanje epalrestata ali njegovega derivata in metode za uporabo le-teh | |
| ZA201206579B (en) | Endoparasiticidal compositions | |
| IL227688A0 (en) | History of aminostatin, their preparation and pharmaceutical preparations containing them | |
| PL2613634T3 (pl) | Kompozycja chwastobójcza i jej zastosowanie |